QIBA SPECT Task Force Friday, February 6, 2015, 9 AM (CT)

Agenda and Additional References

In attendance:

Richard Wahl, MD (Moderator)
Hubert Beaumont, PhD
Ronald Boellaard, PhD
Orest Boyko, MD, PhD
Janice Campbell, PhD
Ming-Kai Chen, MD, PhD
Yuni Dewaraja, PhD
Edward A. Eikman, MD
Eric Frey, PhD
Howard Higley, PhD
John Hoffman, MD

Brian Hutton, PhD

Paul Kinahan, PhD, FIEEE

Michael King, PhD, DABR
Gregory Klein, PhD
Richard Laforest, PhD
Adriaan Lammertsma, PhD
Michael Lassman, PhD
William C. (Rusty) Lavely, MD, CMO
Michael Ljungberg, PhD
Lawrence (Larry) MacDonald, PhD
Robert Miyaoka, PhD
Aaron Nelson, MD

Nancy Obuchowski, PhD

Amy Perkins, PhD

Eric Perlman, MD
John Seibyl, MD, CEO
Daniel Sullivan, MD
John Sunderland, PhD
Zsolt Szabo, MD, PhD
Pierre Tervé, MS
Huseyin Toré, MD
Irene Torres, PhD
Benjamin Tsui, PhD
Timothy Turkington, PhD
Jeffrey Yap, PhD
Brian Zimmerman, PhD

Fiona Miller Joe Koudelik Julie Lisiecki

RSNA

Moderator: Dr. Richard Wahl

Quantitative SPECT Biomarker Exploratory Discussion

1.	Introduction to QIBA efforts	Drs. Sullivan, Kinahan, Wahl
2.	Example of Profile, FDG PET	Drs. Perlman, Wahl
3.	Exploratory Call on SPECT: Review of 10-10/14 call	Dr. Wahl
4.	Review of commercial SPECT products	Dr. Wahl, industry representatives
		(Siemens / GE / Hermes)
5.	Review of recent documents on Q SPECT/brain: EANM, DAT Scan, etc.	Drs. Seibyl, Cole
6.	Review of recent documents on QSPECT/body/dosimetry: JNM/ MIRD	Dr. Dewaraja
7.	Possible "claims"	Group
	 a) Measurement of a large organ ABSOLUTE radioactivity concentration (e.g., liver): Quantitative uptake of radiotracer, such as TcMAA for dosimetry to liver or tumor/organ dosimetry (Dr. Frey or Dr. Dewaraja?) 	
	 b) Measurement of relative or ABSOLUTE radioactivity concentration, or ratios in a small structure: e.g., Striatum for DAT scan (<i>Dr. Seibyl?</i>) c) Thyroid or thyroid cancer (<i>Dr. Lassmann?</i>) 	
	d) Other claims: clinical or research?	
	e) Do we need a claim?	
	i.e., Amyloid claims are still evolving for the Amyloid PET Biomarker Committee	
8.	Is there interest in forming a task force (writing group)?	
9.	Who is willing to join an unpaid, overworked, coalition of the willing to take on this task?	
10.	Next steps?	
	Monthly calls	
	Literature review	

Recommended References:

- Links to documents for SPECT in general and I-131:
- Dr. Dewaraja is currently working on the Lu-177 document with EANM colleagues.
 - o http://jnm.snmjournals.org/content/53/8/1310.long
 - o http://jnm.snmjournals.org/content/54/12/2182.long

Citations:

- Zeintl, et al. Quantitative Accuracy of Clinical ^{99m}Tc SPECT/ CT Using Ordered-Subset Expectation Maximization with **3-Dimensional Resolution Recovery, Attenuation, and Scatter Correction**. *J Nucl Med 2010*; 51:921–928, DOI: 10.2967/jnumed.109.071571.
- Bailey DL and Willowson KP. Quantitative SPECT: Its Time has Come: An Evidence-Based Review of Quantitative SPECT Imaging and Potential Clinical Applications. J Nucl Med 2013; 54:83–89; DOI: 10.2967/jnumed.112.111476.
- Willowson KP, Bailey DL, and Baldock C. **Quantitative SPECT Reconstruction Using CT-derived Corrections.** *Phys. Med. Biol.* **53** (2008) 3099–3112; doi:10.1088/0031-9155/53/12/002

Doodle Poll Follow Up: Those on today's call will be polled to respond if they would like to join this QIBA SPECT Task Force and participate on regular calls.

Upcoming Nuclear Medicine Calls (Fridays, 9 am CT):

• February 13: PET Amyloid Biomarker Ctte

February 20: SPECT Task Force

• February 27: PET Amyloid Biomarker Ctte